<DOC>
	<DOCNO>NCT00794144</DOCNO>
	<brief_summary>The purpose study ass safety study drug , Patanase ( Olopatadine Hydrochloride Nasal Spray 0.6 % ) compare placebo ( inactive substance ) child age 2 less 6 history nasal allergy , ass pharmcokinetics ( study action drug body ) child</brief_summary>
	<brief_title>Safety Pharmacokinetics Patanase Pediatric Patients 2 &lt; 6 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<criteria>Patient must least 2 year age less 6 year age Day 1 ; Parent/legal guardian must willing able give write informed consent must provide consent study ; Patient must positive case history allergic rhinitis symptom least one document positive skin test within 5 year prior Day 1 follow type : skin prick test , intradermal test RAST test ( radioallergosorbent test ) allergen ( ≥ 3 mm wheal great diluent skin prick testing ; ≥ 7 mm wheal great diluent intradermal testing ; positive level 2 great RAST testing ) ; Patient parent/caregiver must willing able make require study visit ; Patient parent/caregiver must able follow instruction ; Nasal exam must confirm absence significant anatomic abnormality , infection , bleeding , mucosal ulceration Screening prior administration test article Day 1 Visit . A finding 'present ' parameter disqualifies patient study , regardless clinical relevance . The need chronic intermittent use prescription overthecounter nasal spray study period ; Use form olopatadine ( e.g. , PATANOL® , PATADAY™ , PATANASE® ) within 7 day Day 1 ; Current recent ( within last 14 day ) use drugs/drug class combination thereof may prolong QT interval ; Patients history evidence nasolacrimal drainage system malfunction abnormality may interfere result study ; Concurrent disease might complicate interfere investigation evaluation study medication ( rhinitis medicamentosa large obstructive nasal polyp ) ; Patients syndromes associate midfacial deformity anatomic nasal deformity may interfere patient 's participation study , identify physical nasal examination Screening Day 1 ; Diagnosis acute sinusitis within 30 day Day 1 diagnosis chronic rhinosinusitis within one year Day 1 ; Congestion would , opinion investigator , interfere successful nasal drug administration/absorption ( either nostril ) ; Upper low respiratory infection within 14 day Day 1 ; Asthma , exception intermittent asthma outline Section 18.5 , Stepwise Approach Managing Asthma Children 04 Years Age , Stepwise Approach Managing Asthma Children 511 Years Age ( 5 ) ; Current recent ( &lt; 6 month ) history severe , unstable , uncontrolled neurological , cardiovascular , gastrointestinal , hematological , hepatic , and/or renal disease , evidence disease physical examination conduct Screening Visit , opinion Investigator would preclude safe participation patient study ; Hypersensitivity olopatadine , benzalkonium chloride , component test article ; History current infection HIV ( Human Immunodeficiency Virus ) , hepatitis B C A , indicate patient 's parent legal guardian response HIV/Hepatitis survey ; Relatives study site staff individual would access clinical study protocol ; A family member individual residing household patient currently enrol study ; Participation investigational study within 30 day entry study ( Day 1 ) , concomitantly study ; Clinically relevant abnormal vital sign ( pulse rate , average systolic diastolic blood pressure ) Screening Day 1 . The range designate normal study . Inclusion patient value outside normal range discretion study investigator ; Normal Cardiovascular Ranges Systolic Blood Pressure — 86 116 mmHg ( millimeter mercury ) Diastolic Blood Pressure —50 78 mmHg Pulse — 75 130 bpm ( beat per minute ) In addition , Alcon Medical Monitor and/or Principal Investigator may declare patient ineligible study base upon sound medical reason .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Pediatric</keyword>
	<keyword>PATANASE</keyword>
</DOC>